Journal of the National Comprehensive Cancer Network Logo

JNCCN is the home in the medical literature for the NCCN Guidelines®, the most widely used guidelines in oncology.

Journal of the National Comprehensive Cancer Network Product Image

Journal of the National Comprehensive Cancer Network

More than 24,500 oncologists and other cancer care professionals across the United States read JNCCN–Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology®, (solicited) review articles elaborating on guideline recommendations, health services research, and case reports highlighting molecular insights in patient care.

JNCCN's vision is to further the mission of NCCN by serving as the primary resource for information on NCCN Clinical Practice Guidelines; innovation in translational medicine; and on scientific studies related to oncology health services research, including quality care and value, patient outcomes, and public policy.

The 2020 Impact Factor for JNCCN is 11.908 as reported by Clarivate in its 2020 Journal Citation Reports (last updated June 2021). JNCCN is indexed by MEDLINE/PUBMED, Chemical Abstracts, EMBASE, EMCare, and Scopus.

Website   |  Advertising   |  Sales   |  Subscribe


Margaret Tempero, MD

Dr. Tempero is Director of the University of California, San Francisco (UCSF) Pancreas Center. She holds the Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science at the UCSF Helen Diller Family Comprehensive Cancer Center.

She previously served as Deputy Director and Interim Director for the University of Nebraska Medical Center Eppley Cancer Center until 1999, Chief Emeritus of the Division of Medical Oncology at UCSF (2000-07) and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center from 2000 to 2012.

Dr. Tempero has served on the Oncology Drug Advisory Committee for the FDA. She is, or has been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board, and the EORTC. She has held many appointments at AACR and ASCO, has served as a member of the ASCO Board of Directors, and was ASCO President in 2004-05.

She has served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. Dr. Tempero has been the Editor-in-Chief of JNCCN since 2014.

View Editorial Board


JNCCN is one of the most-read journals on the oncology market. The current circulation for the publication is 25,859, and its frequency is 13 issues per year. Bonus distribution is available at over a dozen live medical conferences each year. 

Advertising opportunities exist in print, for the website, for electronic table of contents emails, and moreFurther details are available in the media kit. Please contact our advertising representative with any inquiries. 

Journal of the National Comprehensive Cancer Network Rate Card Image

2024 JNCCN Media Kit
Media Kit

Sales Team


David Horowitz
VP Sales, Oncology